Regulatory cells in allergen-specific immunotherapy

Immunotherapy ◽  
2012 ◽  
Vol 4 (4) ◽  
pp. 389-396 ◽  
Author(s):  
Michael B Soyka ◽  
David Holzmann ◽  
Cezmi A Akdis
Keyword(s):  
Specific Immunotherapy ◽  
Regulatory Cells ◽  
Allergen Specific Immunotherapy

scholarly journals Allergen-specific immunotherapy: an update on immunological mechanisms of action

2016 ◽  
Vol 65 (1) ◽  
Author(s):  
G. Ciprandi ◽  
G.L. Marseglia ◽  
M.A. Tosca
Keyword(s):  
Specific Immunotherapy ◽  
T Regulatory Cells ◽  
Sublingual Immunotherapy ◽  
Mechanisms Of Action ◽  
Regulatory Cells ◽  
Allergen Specific Immunotherapy ◽  
Specific Antibodies ◽  
Immunological Mechanisms ◽  
Specific Igg4 ◽  
History Of

Specific immunotherapy (SIT) is the only treatment able to modify the natural history of the allergic subjects. Several aspects of the immunopathological response modified by SIT have been investigated; the first parameter historically studied was the production of allergen-specific antibodies. An increase of allergen-specific IgG4 and a decrease of IgE appear after SIT. A shift from Th2-polarized immune response toward Th1-oriented pattern has been reported after SIT. More recently, a crucial role for a subpopulation of T cells has been evidenced: T regulatory cells (Treg). Allergic patients have a defect of Tregs. SIT is able of inducing a specific Treg response. Sublingual immunotherapy is an alternative route of administration for SIT. Recent evidence shows that SLIT is also able of inducing a Treg response as detected by IL- 10 production.

Mechanisms of Allergen-Specific Immunotherapy: T-Regulatory Cells and More

2006 ◽  
Vol 26 (2) ◽  
pp. 207-231 ◽  
Author(s):  
Johan Verhagen ◽  
Kurt Blaser ◽  
Cezmi A. Akdis ◽  
Mübeccel Akdis
Keyword(s):  
Specific Immunotherapy ◽  
T Regulatory Cells ◽  
Regulatory Cells ◽  
Allergen Specific Immunotherapy

T Regulatory Cells in Allergen-Specific Immunotherapy

2005 ◽  
Vol 24 (5-6) ◽  
pp. 533-548 ◽  
Author(s):  
Johan Verhagen ◽  
Alison Taylor ◽  
Kurt Blaser ◽  
Mübeccel Akdis ◽  
Cezmi A. Akdis
Keyword(s):  
Specific Immunotherapy ◽  
T Regulatory Cells ◽  
Regulatory Cells ◽  
Allergen Specific Immunotherapy

Immunotheraphy in Allergic Diseases

2018 ◽  
Vol 24 (11) ◽  
pp. 1174-1194
Author(s):  
Albert Roger ◽  
Maria Basagana ◽  
Aina Teniente-Serra ◽  
Nathalie Depreux ◽  
Yanina Jurgens ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Allergic Diseases ◽  
Specific Ige ◽  
World Population ◽  
Allergen Specific Immunotherapy ◽  
Routes Of Administration ◽  
Disease Modifying Therapy ◽  
History Of ◽  
Ige Mediated ◽  
Special Case

The prevalence of allergic diseases is increasing worldwide. It is estimated that more than 30% of the world population is now affected by one or more allergic conditions and a high proportion of this increase is in young people. The diagnosis of allergy is dependent on a history of symptoms on exposure to an allergen together with the detection of allergen-specific IgE. Accurate diagnosis of allergies opens up therapeutic options. Allergen specific immunotherapy is the only successful disease-modifying therapy for IgE-mediated allergic diseases. New therapeutic strategies have been developed or are currently under clinical trials. Besides new routes of administration, new types of allergens are being developed. The use of adjuvants may amplify the immune response towards tolerance to the antigens. In this review, we analyze different antigen-specific immunotherapies according to administration route, type of antigens and adjuvants, and we address the special case of food allergy.

Planning and approach to allergen-specific immunotherapy in polyallergic patients

Immunotherapy ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 577-585
Author(s):  
Nerin N Bahceciler ◽  
Ozel Yuruker
Keyword(s):  
Clinical Management ◽  
Respiratory Diseases ◽  
Specific Immunotherapy ◽  
Clinical Symptoms ◽  
Allergen Specific Immunotherapy ◽  
Stepwise Approach ◽  
Future Studies ◽  
Disease Modifying ◽  
Management Recommendations ◽  
Disease Modifying Treatment

Allergy immunotherapy (AIT) is currently the only disease-modifying treatment for allergic-respiratory diseases. Polysensitization may increase the severity of current disease resulting in subsequent asthma development in patients with allergic rhinitis. Due to the absence of general recommendations for the practical approach to polysensitized patients, clinical management is not standardized. The correlation between sensitizations and clinical symptoms, elimination of possible pollen cross-reactivities and principles of homologous allergen groups will guide the allergists to deduce the most relevant allergens for AIT. In the highlight of the previously proposed approach strategies to polyallergic patients, hereby we propose a revised practical stepwise approach based on the current European Medicine Agency (EMA) guidelines. However, more supporting data from well-designed, controlled, future studies are needed to improve clinical management recommendations for AIT in polyallergic patients.

Sign in / Sign up

Export Citation Format

Share Document